Clinics in Dermatology
Volume 25, Issue 3 , Pages 303-311 , May 2007

Systemic evaluation of a potential cutaneous sarcoidosis patient

  • Ulrich Costabel, MD

      Affiliations

    • Department of Pneumology/Allergy, Ruhrlandklinik Essen, D-45239 Essen, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49 201 433 4020; fax: +49 201 433 4029.
    • ,
  • Josune Guzman, MD

      Affiliations

    • Department of Pneumology/Allergy, Ruhrlandklinik Essen, D-45239 Essen, Germany
    • ,
  • Robert P. Baughman, MD

      Affiliations

    • General and Experimental Pathology, Ruhr University, Bochum, D-44801 Bochum, Germany

References 

  1. Hunninghake GW, Costabel U, Ando M, et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis. 1999;16:149–173
  2. Pietinalho A, Ohmichi M, Lofroos AB, et al. The prognosis of sarcoidosis in Finland and Hokkaido, Japan. A comparative five-year study of biopsy-proven cases. Sarcoidosis Vasc Diffuse Lung Dis. 2000;17:158–166
  3. Loddenkemper R, Kloppenborg A, Schoenfeld N, et al. Clinical findings in 715 patients with newly detected pulmonary sarcoidosis—results of a cooperative study in former West Germany and Switzerland. WATL Study Group. Wissenschaftliche Arbeitsgemeinschaft fur die Therapie von Lungenkrankheitan. Sarcoidosis Vasc Diffuse Lung Dis. 1998;15:178–182
  4. Baughman RP, Teirstein AS, Judson MA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med. 2001;164:1885–1889
  5. deVries J, Rothkrantz-Kos S, Dieijen-Visser MP, et al. The relationship between fatigue and clinical parameters in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2004;21:127–136
  6. Baughman RP, Strohofer SA, Buchsbaum J, et al. Release of tumor necrosis factor by alveolar macrophages of patients with sarcoidosis. J Lab Clin Med. 1990;115:36–42
  7. Mana J, Gomez VC, Montero A, et al. Lofgren's syndrome revisited: a study of 186 patients. Am J Med. 1999;107:240–245
  8. Neville E, Walker AN, James DG. Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients. Q J Med. 1983;208:525–533
  9. Judson MA, Baughman RP, Thompson BW, et al. Two year prognosis of sarcoidosis: the ACCESS experience. Sarcoidosis Vasc Diffuse Lung Dis. 2003;20:204–211
  10. Yeager H, Rossman MD, Baughman RP, et al. Pulmonary and psychosocial findings at enrollment in the ACCESS study. Sarcoidosis Vasc Diffuse Lung Dis. 2005;22:147–153
  11. Baughman RP, Iannuzzi MC, Lower EE, et al. Use of fluticasone in acute symptomatic pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2002;19:198–204
  12. Shorr AF, Torrington KG, Hnatiuk OW. Endobronchial biopsy for sarcoidosis: a prospective study. Chest. 2001;120:109–114
  13. Baughman RP, Shipley RT, Loudon RG, et al. Crackles in interstitial lung disease. Comparison of sarcoidosis and fibrosing alveolitis. Chest. 1991;100:96–101
  14. Scadding JG. Prognosis of intrathoracic sarcoidosis in England. Br Med J. 1961;4:1165–1172
  15. Pietinalho A, Ohmichi M, Hiraga Y, et al. The mode of presentation of sarcoidosis in Finland and Hokkaido, Japan. A comparative analysis of 571 Finnish and 686 Japanese patients. Sarcoidosis. 1996;13:159–166
  16. Winterbauer RH, Belic N, Moores KD. A clinical interpretation of bilateral hilar adenopathy. Ann Intern Med. 1973;78:65–71
  17. Subramanian I, Flaherty KR, Martinez FJ. Pulmonary function testing in sarcoidosis. In:  Baughman RP editors. Sarcoidosis. New York: Taylor and Francis; 2006;p. 415–433
  18. Bechtel JJ, Starr TI, Dantzker DR, et al. Airway hyperreactivity in patients with sarcoidosis. Am Rev Respir Dis. 1981;124:759–761
  19. Shorr AF, Torrington KG, Hnatiuk OW. Endobronchial involvement and airway hyperreactivity in patients with sarcoidosis. Chest. 2001;120:881–886
  20. Ohara K, Judson MA, Baughman RP. Clinical aspects of ocular sarcoidosis. In:  Drent M,  Costabel U editor. Sarcoidosis. Wakefield, UK: The Charlesworth Group; 2005;p. 188–209
  21. Bradley DA, Baughman RP, Raymond L, et al. Ocular manifestations of sarcoidosis. Semin Respir Crit Care Med. 2002;23:543–548
  22. Rizzato G, Fraioli P, Montemurro L. Nephrolithiasis as a presenting feature of chronic sarcoidosis. Thorax. 1995;50:555–559
  23. Lower EE, Broderick JP, Brott TG, et al. Diagnosis and management of neurologic sarcoidosis. Arch Intern Med. 1997;157:1864–1868
  24. Judson MA. Hepatic, splenic, and gastrointestinal involvement with sarcoidosis. Semin Respir Crit Care Med. 2002;23:529–543
  25. Warshauer DM, Molina PL, Hamman SM, et al. Nodular sarcoidosis of the liver and spleen: analysis of 32 cases. Radiology. 1995;195:757–762
  26. Baughman RP, Koehler A, Bejarano PA, et al. Role of liver function tests in detecting methotrexate-induced liver damage in sarcoidosis. Arch Intern Med. 2003;163:615–620
  27. Lower EE, Baughman RP. Prolonged use of methotrexate for sarcoidosis. Arch Intern Med. 1995;155:846–851
  28. Deng JC, Baughman RP, Lynch JPI. Cardiac involvement in sarcoidosis. Semin Respir Crit Care Med. 2002;23:513–528
  29. Suzuki T, Kanda T, Kubota S, et al. Holter monitoring as a noninvasive indicator of cardiac involvement in sarcoidosis. Chest. 1994;106:1021–1024
  30. Skold CM, Larsen FF, Rasmussen E, et al. Determination of cardiac involvement in sarcoidosis by magnetic resonance imaging and Doppler echocardiography. J Intern Med. 2002;252:465–471
  31. Wagner MT, Marion SD, Judson MA. The effects of fatigue and treatment with methylphenidate on sustained attention in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2005;22:235
  32. Glazer CS, Newman LS. Beryllium as a model for sarcoidosis. In:  Baughman RP editors. Sarcoidosis. New York: Taylor and Francis Group; 2006;p. 321–343
  33. Newman LS, Rose CS, Bresnitz EA, et al. A case control etiologic study of sarcoidosis: environmental and occupational risk factors. Am J Respir Crit Care Med. 2004;170:1324–1330
  34. Rybicki BA, Iannuzzi MC, Frederick MM, et al. Familial aggregation of sarcoidosis: a case-control etiologic study of sarcoidosis (ACCESS). Am J Respir Crit Care Med. 2001;164:2085–2091
  35. Judson MA, Baughman RP, Teirstein AS, et al. Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. Sarcoidosis Vasc Diffuse Lung Dis. 1999;16:75–86
  36. Baughman RP, duBois RM, Lower EE. Sarcoidosis. Lancet. 2003;361:1111–1118
  37. Gronhagen-Riska C, Selroos O, Wagar G, et al. Angiotensin-converting enzyme. II. Serum activity in early and newly diagnosed sarcoidosis. Scand J Respir Dis. 1979;60:94–101
  38. Lieberman J. Elevation of serum angiotensin converting enzyme (ACE) level in sarcoidosis. Am J Med. 1975;59:365–372
  39. Baughman RP, Costabel U. Markers of sarcoidosis. In:  Baughman RP editors. Sarcoidosis. New York: Taylor and Francis Group; 2006;p. 435–462
  40. Lieberman J, Nosal A, Schlessner A, et al. Serum angiotensin-converting enzyme for diagnosis and therapeutic evaluation of sarcoidosis. Am Rev Respir Dis. 1979;120:329–335
  41. Lieberman J. The specificity and nature of serum-angiotensin-converting enzyme (serum ACE) elevations in sarcoidosis. Ann N Y Acad Sci. 1976;278:488–497
  42. Newman LS, Orton R, Kreiss K. Serum angiotensin converting enzyme activity in chronic beryllium disease. Am Rev Respir Dis. 1992;146:39–42
  43. Silverstein E, Schussler GC, Friedland J. Elevated serum angiotensin-converting enzyme in hyperthyroidism. Am J Med. 1983;75:233–236
  44. Tomita H, Ina Y, Sugiura Y, et al. Polymorphism in the angiotensin-converting enzyme (ACE) gene and sarcoidosis. Am J Respir Crit Care Med. 1997;156:255–259
  45. Rigat B, Hubert C, Alhenc-Gelas F, et al. An insertion/deletion polymorphism in the angiotensin I–converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990;86:1343–1346
  46. DeRemee RA, Rohrbach MS. Serum angiotensin-converting enzyme activity in evaluating the clinical course of sarcoidosis. Ann Intern Med. 1980;92:361–365
  47. Baughman RP, Ploysongsang Y, Roberts RD, et al. Effects of sarcoid and steroids on angiotensin-converting enzyme. Am Rev Respir Dis. 1983;128:631–633
  48. Romer FK, Ahlbom G, Jensen JU. Relationship between angiotensin-converting enzyme and lysozyme in sarcoidosis. Eur J Respir Dis. 1982;63:330–336
  49. Baughman RP, Fernandez M, Bosken CH, et al. Comparison of gallium-67 scanning, bronchoalveolar lavage, and serum angiotensin-converting enzyme levels in pulmonary sarcoidosis. Predicting response to therapy. Am Rev Respir Dis. 1984;129:676–681
  50. Sulica R, Teirstein AS, Kakarla S, et al. Distinctive clinical, radiographic, and functional characteristics of patients with sarcoidosis-related pulmonary hypertension. Chest. 2005;128:1483–1489
  51. Kohn H, Klech H, Mostbeck A, et al. 67Ga scanning for assessment of disease activity and therapy decisions in pulmonary sarcoidosis in comparison to chest radiography, serum ACE and blood T-lymphocytes. Eur J Nucl Med. 1982;7:413–416
  52. Taaleb K, Kaiser KP, Wieler H. Elevated uptake of F-18 FDG in PET scans in nonmalignant disease. Clin Nucl Med. 2000;25:939–940
  53. Hendrickx BW, van Herpen CM, Bonenkamp JJ, et al. Positive positron emission tomography scan in sarcoidosis and two challenging cases of metastatic cancer. CASE 1. Mediastinal sarcoidosis in a melanoma patient treated with interferon. J Clin Oncol. 2005;23:8906–8907
  54. Reynolds HY. Use of bronchoalveolar lavage in humans—past necessity and future imperative. Lung. 2000;178:271–293
  55. Baughman RP, Drent M. Role of bronchoalveolar lavage in interstitial lung disease. Clin Chest Med. 2001;22:331–341
  56. Costabel U, Guzman J. Bronchoalveolar lavage in interstitial lung disease. Curr Opin Pulm Med. 2001;7:255–261
  57. Welker L, Jorres RA, Costabel U, et al. Predictive value of BAL cell differentials in the diagnosis of interstitial lung diseases. Eur Respir J. 2004;24:1000–1006
  58. Drent M, Jacobs JA, Cobben NA, et al. Computer program supporting the diagnostic accuracy of cellular BALF analysis: a new release. Respir Med. 2001;95:781–786
  59. Baughman RP, Dohn MN, Loudon RG, et al. Bronchoscopy with bronchoalveolar lavage in tuberculosis and fungal infections. Chest. 1991;99:92–97
  60. Grutters JC, Fellrath JM, Mulder L, et al. Serum soluble interleukin-2 receptor measurement in patients with sarcoidosis: a clinical evaluation. Chest. 2003;124:186–195
  61. Lawrence EC, Brousseau KP, Berger MB, et al. Elevated concentrations of soluble interleukin-2 receptors in serum samples and bronchoalveolar lavage fluids in active sarcoidosis. Am Rev Respir Dis. 1988;137:759–764
  62. Ziegenhagen MW, Benner UK, Zissel G, et al. Sarcoidosis: TNF-alpha release from alveolar macrophages and serum level of sIL-2R are prognostic markers. Am J Respir Crit Care Med. 1997;156:1586–1592
  63. Gronhagen-Riska C, Selroos O, Niemisto M. Angiotensin converting enzyme. V. Serum levels as monitors of disease activity in corticosteroid-treated sarcoidosis. Eur J Respir Dis. 1980;61:113–122
  64. Baughman RP, Judson MA, Teirstein AS, et al. Thalidomide for chronic sarcoidosis. Chest. 2002;122:227–232

PII: S0738-081X(07)00062-4

doi: 10.1016/j.clindermatol.2007.03.008

Clinics in Dermatology
Volume 25, Issue 3 , Pages 303-311 , May 2007

Article Tools

* Image Usage & Resolution